Vandetanib (ZD6474)

目录号:S1046

Vandetanib (ZD6474) Chemical Structure

Molecular Weight(MW): 475.35

Vandetanib (ZD6474)是一种有效的VEGFR2抑制剂,在无细胞试验中IC50为40 nM。同时,也抑制VEGFR3EGFR,IC50分别为110 nM 和500 nM。对PDGFRβ, Flt-1, Tie-2 和FGFR1作用效果不大,IC50为 1.1-3.6 μM, 对MEK, CDK2, c-Kit, erbB2, FAK, PDK1, Akt 和 IGF-1R几乎没有作用效果,IC50>10 μM。

规格 价格 库存 购买数量  
RMB 1211.82 现货
RMB 3835.98 现货
RMB 5468.77 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献22篇:

客户使用该产品的7个实验数据:

  • (A) Representative in vivo bioluminescence of mice at and during time of treatment. Derived cell lines with either BCR-ABL1 WT or V299L was tail-vein injected into immunocompetent recipient mice. Initial imaging was performed at day 10 post-transplantation. Mice were subsequently treated once daily with vehicle, 10 mg/kg dasatinib, 50 mg/kg imatinib, 50 mg/kg vandetanib, or 50 mg/kg foretinib.
    (B) Fold change in total whole-mouse bioluminescence signal between post- and pre-treatment. Mice bearing BCR-ABL1 V299L ALLs showed significant tumor burden reduction upon treatment with foretinib or vandetanib. Statistical significance determined by Mann-Whitney test. *p < 0.05, **p < 0.01.

    Cell, 2016, 165(1):234-46.. Vandetanib (ZD6474) purchased from Selleck.

    Vandetanib reduced extracellular nitrite levels in endothelial cells. MS1 endothelial cells (ECs) were incubated with 1 mol/L of vandetanib or matched vehicle (dimethyl sulfoxide [DMSO]), 50 ng/mL of vascular endothelial growth factor (VEGF) or matched vehicle (PBS; 0.5 hours), and L-arginine and soluble N-ethylmaleamide sensitive factor attachment protein (SNAP) added (1.5 hours). Vandetanib lowered nitrite levels in MS1 Ecs (*P0.0003). VEGF was used a positive control and increased nitrite levels (**P0.02). These findings indicate that vandetanib lowered endothelial cell NO levels.

    Hypertension 2011 58, 85-92. Vandetanib (ZD6474) purchased from Selleck.

  • Vandetanib reduced phosphorylation of Akt in endothelial cells (ECs). MS1 ECs were incubated with 1 μmol/L of vandetanib or matched vehicle (dimethyl sulfoxide [DMSO]; 1 hour). Western blotting analysis showed that vandetanib decreased phosphorylation of Akt (S473) in MS1 ECs (*P<0.01; n=6 per group, studies done in triplicate). These findings show that vandetanib reduced Akt activity.

    Hypertension 2011 58, 85-92. Vandetanib (ZD6474) purchased from Selleck.

    Vandetanib increases membrane localization of endothelial NO synthase (eNOS). MS1 endothelial cells (ECs) were incubated with 1 μmol/L of vandetanib or matched vehicle (dimethyl sulfoxide [DMSO]). Western blotting analysis showed that vandetanib increases membrane localization of eNOS compared with control (*P<0.04; n=4 per group, studies done in triplicate). These findings show that vandetanib increased the membrane localization of eNOS compared with control.

    Hypertension 2011 58, 85-92. Vandetanib (ZD6474) purchased from Selleck.

  • (H) Anti-pSTAT3Y705, total STAT3, pSRCy416 of RWPE-1 transfectants treated for 6 hours with vandetanib at the indicated concentrations. Actin was used as loading control.

    J Cancer, 2017, 8(1):140-145. Vandetanib (ZD6474) purchased from Selleck.

    LS-007 inhibits CDK1/CDK7/CDK9 activity in AL cells. HL-60 (A), CCRF-CEM (B) cells were treated with increasing concentrations of LS-007 or flavopiridol for 2 h, and cell lysates were collected and examined by immunoblotting with the indicated antibodies.

    Acta Pharmacol Sin, 2016, 37(11):1481-1489. Vandetanib (ZD6474) purchased from Selleck.

  • Breast cancer cells were pretreated with 100ng/ml EGF for 15 min and then treated with the indicated concentrations of Vandetanib for 24 hours.

     

     

    Dr. Zhang of Tianjin Medical University. Vandetanib (ZD6474) purchased from Selleck.

产品安全说明书

VEGFR抑制剂选择性比较

生物活性

产品描述 Vandetanib (ZD6474)是一种有效的VEGFR2抑制剂,在无细胞试验中IC50为40 nM。同时,也抑制VEGFR3EGFR,IC50分别为110 nM 和500 nM。对PDGFRβ, Flt-1, Tie-2 和FGFR1作用效果不大,IC50为 1.1-3.6 μM, 对MEK, CDK2, c-Kit, erbB2, FAK, PDK1, Akt 和 IGF-1R几乎没有作用效果,IC50>10 μM。
靶点
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
EGFR [1]
(Cell-free assay)
40 nM 110 nM 500 nM
体外研究

Vandetanib 也抑制VEGFR3和EGFR,IC50分别为110 nM 和500 nM。Vandetanib 对PDGFRβ, Flt-1, Tie-2 和FGFR1作用效果不大,IC50为 1.1-3.6 μM, 而对MEK, CDK2, c-Kit, erbB2, FAK, PDK1, Akt 和 IGF-1R几乎没有作用效果,IC50 > 10 μM。Vandetanib 抑制VEGF-, EGF- 和 bFGF-刺激的 HUVEC 增殖,IC50分别为60 nM, 170 nM 和 800 nM, 而对基底内皮细胞生长几乎没有作用效果。Vandetanib 抑制肿瘤细胞生长,IC50 为 2.7 μM (A549) 到13.5 μM (Calu-6)。[1] Vandetanib抑制basal ABCG2-ATP酶。亲本和表达ABCG2的A431细胞对 Vandetanib具有相似的敏感性。EGFR 抑制剂处理A431细胞,降低pEGFR水平,而Vandetanib 处理时,抑制效果温和。Gefitinib, Pelitinib 和 Neratinib完全抑制 ABCG2调节的Mitoxantrone从 A431/ABCG2细胞中外排,而Vandetanib只具有微弱且不可测量的抑制效果,与 特点ABCG2抑制剂Ko143类似。[2] Vandetanib抑制PC3wt 和PC3R细胞系,IC50分别为13.3 μM和11.5 μM。[3] Vandetanib 作用于HUVEC,抑制VEGFR-2磷酸化,作用于肝癌细胞,抑制EGFR磷酸化,且抑制细胞增殖。[4] Vandetanib 作用于GEO 和 OVCAR-3 细胞,使细胞在G0-G1期累积,作用于OVCAR-3, ZR-75-1, MCF-10A ras, 和 GEO 细胞,促进凋亡。Vandetanib 作用于小鼠NIH-EGFR 成纤维细胞和人类 MCF-10A ras 乳腺癌细胞(这两种细胞都过量表达人类EGFR),抑制EGFR磷酸化,这种作用存在剂量依赖性。Vandetanib 作用于有功能性EGFR但是缺失VEGFR-2的人类细胞系 (乳腺,结肠,胃,和卵巢),抑制软琼脂生长,这种作用具有剂量依赖性。[5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SN179  NWC1bZVXTnWwY4Tpc44hSXO|YYm= NWLPW3ZSPTBy4pEJcm3DqA>? M{LnfVE3KGh? NGPwXpFqdmO{ZXHz[ZMhS1iFUkSg[ZhxemW|c3nvckB{cWewaX\pZ4FvfGy7 NYX5XG43OjV4N{[2PVE>
SN186 M4rBbmZ2dmO2aX;uJGF{e2G7 M2rqc|UxOOLCiX7NxsA> NGTKWJkyPiCq MXTpcoNz\WG|ZYOgR3hEWjRiZYjwdoV{e2mxbjDzbYdvcW[rY3HueIx6 MVWyOVY4PjZ7MR?=
SN179  NYjIeZZ6TnWwY4Tpc44hSXO|YYm= MY[1NFDjiImwTdMg NIPKOJoyPiCq NF;FcWpmdmijbnPld{B1cGViQ2jDUFEzKGSrcnXjeIVlKG2rZ4LheIlwdg>? NWW1ZoZmOjV4N{[2PVE>
SN179  NGLESY1HfW6ldHnvckBCe3OjeR?= MVW1NFDjiImwTdMg NITORm0yPiCq NF63UI5qdmO{ZXHz[ZMh[mG|YXygcYloemG2aX;uxsA> NUTqbYpYOjV4N{[2PVE>
Jurkat M4W0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37h[|czyqCqwrC= NHvkPYtIUTVyPUGuOUDDuSByLkKg{txO NFLnflczPDZ6MUKwOS=>
K-562 M3HpXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TFb|czyqCqwrC= NVfWTW9DT0l3ME2xMlghyrFiMD6xJO69VQ>? NFHGOJEzPDZ6MUKwOS=>
NCTC-2544 NX;mXHJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVm3NuKhcMLi NXfEW4o6T0l3ME20MlYhyrFiMD6zJO69VQ>? M4XTO|I1PjhzMkC1
A-431 NYT4V4lGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUGxZlJnPzMEoHlCpC=> NEPycIpIUTVyPUKuOEDDuSByLkOg{txO NGjaWXQzPDZ6MUKwOS=>
SK-N-SH Ml\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLPVlkyOC54MkWtNlAh|ryP NEXwbFM1QCCq M4DvTmROW09? NEOwd25qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M2KxSVI1Ozl7MEe0
SH-SY5Y MmHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Dz[|AvPjJ3LUKwJO69VQ>? MVq0PEBp MkKySG1UVw>? MoXFbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M3vOclI1Ozl7MEe0
SK-N-SH NGDhNWRCeG:ydH;zbZNqKEG|c3H5 MXy1M|ExNzJyIN88US=> MoLtOFghcA>? M3\wbWROW09? MlrXbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= MkjVNlQ{QTlyN{S=
SH-SY5Y NHX5ZZFCeG:ydH;zbZNqKEG|c3H5 MVy1M|ExNzJyIN88US=> MojzOFghcA>? NGThdnFFVVOR NHTkeWZqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 Mk\VNlQ{QTlyN{S=
SK-N-SH M4LVWmZ2dmO2aX;uJGF{e2G7 NEPLVlE2NzFyL{KwJO69VQ>? NV3vVJF1PDhiaB?= NWS4c2puTE2VTx?= MlHxbY5lfWOnczDHNUBxcGG|ZTDj[YxtKGO7Y3zlJIFzemW|dB?= Mn;DNlQ{QTlyN{S=
SH-SY5Y NXj0bFR3TnWwY4Tpc44hSXO|YYm= M2LvW|UwOTBxMkCg{txO M4L6fVQ5KGh? MWHEUXNQ NEHm[mRqdmS3Y3XzJGcyKHCqYYPlJINmdGxiY4njcIUh[XK{ZYP0 NHTvZoEzPDN7OUC3OC=>
SK-N-SH NIXaUHJHfW6ldHnvckBCe3OjeR?= M2DkOlEwPS9zMDFOwG0> MUG0PEBp NVvz[Zp7TE2VTx?= M4TKb4lvcGmkaYTzJHJGXCCyaH;zdIhwenmuYYTpc44> MlHRNlQ{QTlyN{S=
SH-SY5Y NF\F[WpHfW6ldHnvckBCe3OjeR?= M{Cw[VEwPS9zMDFOwG0> NX21NW1UPDhiaB?= M2LpTWROW09? MVXpcohq[mm2czDSSXQheGixc4Doc5J6dGG2aX;u MY[yOFM6QTB5NB?=
SK-N-SH NX3IOGN6TnWwY4Tpc44hSXO|YYm= Mo\sOU8yOCEQvF2= M3rxdlQ5KGh? NFTGOYFFVVOR NXO4[2FCcW6qaXLpeJMhcHWvYX6gUmIh[2WubDDtbYdz[XSrb36= Ml\MNlQ{QTlyN{S=
SH-SY5Y MVvGeY5kfGmxbjDBd5NigQ>? NFezUYU2NzFyIN88US=> NYDMTWhYPDhiaB?= MVLEUXNQ MVTpcohq[mm2czDoeY1idiCQQjDj[YxtKG2rZ4LheIlwdg>? NWPXcYhqOjR|OUmwO|Q>
SK-N-SH MYHGeY5kfGmxbjDBd5NigQ>? MXG1M|ExKM7:TR?= NFfLXok1QCCq NGnmWVdFVVOR M1X4WIlvcGmkaYTzJIh2dWGwIF7CJINmdGxiaX72ZZNqd25? NGPCOWkzPDN7OUC3OC=>
SH-SY5Y NFrZU4FHfW6ldHnvckBCe3OjeR?= MljrOU8yOCEQvF2= NUnOUodCPDhiaB?= NH[2TG9FVVOR Mk[xbY5pcWKrdIOgbJVu[W5iTlKgZ4VtdCCrbo\hd4lwdg>? MXyyOFM6QTB5NB?=
SK-N-SH M4Lpb2Z2dmO2aX;uJGF{e2G7 NITyelY2KM7:TR?= MU[yOE81QC95MjDo NWDhdnFmTE2VTx?= NH3LVXR{fXCycnXzd4V{KHSqZTDlfJBz\XO|aX;uJI9nKEO[Q2K0JIFv\CCPTWCxOEBuWk6D NYWxT3VUOjR|OUmwO|Q>
SH-SY5Y NX7VPGhPTnWwY4Tpc44hSXO|YYm= MW[1JO69VQ>? MY[yOE81QC95MjDo MWLEUXNQ MWXzeZBxemW|c3XzJJRp\SCneIDy[ZN{cW:wIH;mJGNZS1J2IHHu[EBOVVBzNDDtVm5C MVSyOFM6QTB5NB?=
SK-N-SH NGrBWIZHfW6ldHnvckBCe3OjeR?= MYK1JO69VQ>? NEThSoI1QC95MjDo NFTrdZNFVVOR NHrKXYl{fXCycnXzd4V{KGW6cILld5Nqd25ib3[geIhmKEO[Q2K0JIFv\CCPTWCxOEBxem:2ZXnu NG\YeGgzPDN7OUC3OC=>
SH-SY5Y M3TZfWZ2dmO2aX;uJGF{e2G7 Ml31OUDPxE1? M2\BTlQ5Nzd{IHi= NGnDZnlFVVOR NE\1bXh{fXCycnXzd4V{KGW6cILld5Nqd25ib3[geIhmKEO[Q2K0JIFv\CCPTWCxOEBxem:2ZXnu NH62R3MzPDN7OUC3OC=>
HMEpC MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnSW256OSCwTT2xNFAh|ryP NVi0ZYtuPDkEoHlCpC=> Ml31SG1UVw>? NGH1SJRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M17jcVI1OTN6OESz
MCF-7 MknES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfnNUBvVS1zMECg{txO MUm0POKhcMLi MWfEUXNQ M3HvOYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz M4rablI1OTN6OESz
ZR-75-1 NV7NXoE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTubYp2OSCwTT2xNFAh|ryP MY[0POKhcMLi MVLEUXNQ NV:yOnl5cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M{C0NVI1OTN6OESz
MDA-MB-231 MnTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1[4ZVEhdk1vMUCwJO69VQ>? M1TaelQ5yqCqwrC= NHnkO3VFVVOR MYfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> Moq1NlQyOzh6NEO=
MDA-MB-468 MorUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojrNUBvVS1zMECg{txO NEjvWGI1QMLiaNMg MYTEUXNQ MXfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NGjGbHczPDF|OEi0Ny=>
T-47-D MlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY[xJI5ONTFyMDFOwG0> M1fCdFQ5yqCqwrC= MlvySG1UVw>? M{DhT4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NWHx[VZwOjRzM{i4OFM>
U251  NH7xXY9HfW6ldHnvckBCe3OjeR?= NETkXFkzNzRxOPMAje696oT|wrC= NVnlbW5[Pi9zMj:yOEBp MWPEUXNQ NXvFOGRMcW6lcnXhd4V{KHSqZTDMR|MuUUlibHX2[YwhcW5iYTD0bY1mNWSncHXu[IVvfCCjbnSg[I9{\S2mZYDlcoRmdnRibXHucoVz NWjYfGZpOjN5OUm4OVI>
U87MG NVTQfFBWTnWwY4Tpc44hSXO|YYm= NGTFPZozNzRxOPMAje696oT|wrC= M1\UflYwOTJxMkSgbC=> M3GyRWROW09? MYXpcoNz\WG|ZYOgeIhmKEyFMz3JTUBt\X[nbDDpckBiKHSrbXWt[IVx\W6mZX70JIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NFnxZ40zOzd7OUi1Ni=>
U251  M4PZTWZ2dmO2aX;uJGF{e2G7 M4TIVlTjiIoQvPMEt:Kh Mn\XNk83NzF{IHi= M{PtU2ROW09? MWLzeZBxemW|c3XzJIJie2GuIHzleoVteyCxZjDwbI9{eGixconsZZRqd25ib3[gV|YhMFN{M{WvNlM3MSxiNFWtRnAyKCiWM{evOFYqNCCjbnSgRYt1KCiVNEezLUBqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7lduKh NWD5T5VNOjN5OUm4OVI>
U87MG Mn3USpVv[3Srb36gRZN{[Xl? NHnLcWc16oDLzs|iiNPDqA>? NVHIe4djOi94L{GyJIg> MXTEUXNQ NXy4TmI6e3WycILld5NmeyCkYYPhcEBt\X[nbIOgc4YheGixc4Doc5J6dGG2aX;uJI9nKFN4IDjTNlM2NzJ|NjmsJFRGNUKSMTCoWFM4NzR4KTygZY5lKEGtdDCoV|Q4OyliaX6gZUB1cW2nLXTldIVv\GWwdDDtZY5v\XMEoB?= MXyyN|c6QTh3Mh?=
H1650  MmjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTNwNdMxNU4zKM7:TR?= Mk\nNlMzPzR5NUi=
HUVECs  NFP1coJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUj1[no{PzJiaB?= MVjJR|UxyqB;IEeuNUDPxG2xbD;M NVzIbVd1OjJ4MUGwNlc>
KYN-2  NYG1fIdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPFO|IhcA>? MVLJR|UxyqB;IEiuNUDPxG2xbD;M MofWNlI3OTFyMke=
HuH-7  NX3pWI5TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXKblI4OiCq MX7JR|UxyqB;IEmuOEDPxG2xbD;M NX[3ZXlkOjJ4MUGwNlc>
HUVECs  NFTrPHZHfW6ldHnvckBCe3OjeR?= M3XlPFEwPS9zMDFOwG0> MUixJIg> MXPzbYdvcW[rY3HueIx6KGmwaHnibZR{KF[HR1\SMVIheGixc4Doc5J6dGG2aX;u MoSxNlI3OTFyMke=
HAK1-B NEfMSXZHfW6ldHnvckBCe3OjeR?= NX;Xc45pOS93L{GwJO69VQ>? NX\wSXY2OSCq NF\VZ5F{fXCycnXzd4V{KEWJRmKgdIhwe3Cqb4L5cIF1cW:w M4C0NVIzPjFzMEK3
UM-22A MmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3znNFAuPiEQvF2= MX63NkBp M4q0SGROW09? MUTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NHH3WZEzOjNyN{ezOS=>
UM-22B NUHCWHh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWWwMVYh|ryP MnLJO|IhcA>? MmjwSG1UVw>? M2D2b4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MmDINlI{ODd5M{W=
PCI-37A NUPUUXdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fTTlAuPiEQvF2= NV3a[GNPPzJiaB?= NFjteldFVVOR MUXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> M2jzSVIzOzB5N{O1
PCI-37B MofnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrGe2V5OC14IN88US=> M{jnd|czKGh? NFPYT2VFVVOR MoPFbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MmrkNlI{ODd5M{W=
PCI-15B NWL3[5h{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrtNItLOC14IN88US=> NEnYeHg4OiCq M321V2ROW09? M{LESIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MVuyNlMxPzd|NR?=
SCC-25 NWfSPJRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7jbWs6OC14IN88US=> MoPEO|IhcA>? NV3qRox2TE2VTx?= NEe3emdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M3O2WVIzOzB5N{O1
UM-22A MnXPSpVv[3Srb36gRZN{[Xl? NIjyVHgxNTFyIN88US=> NFfSOXAzPCCq Mmj2SG1UVw>? NXvsbWs2cW6qaXLpeJMhfGinIHHjeIl3[XSrb36gc4YhfGinIFXHSnIhfHm{b4PpcoUhc2mwYYPlJIFv\CCjbIPvJIRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBxcG:|cHjvdplt[XSnZDDmc5JueyCxZjD0bIUh\G:5boP0doVidSC|aXfuZYxqdmdiZXzlcYVvfHNuIGPURXQ{KGGwZDDNRXBM Mn7TNlI{ODd5M{W=
UM-22B NXLxO5BETnWwY4Tpc44hSXO|YYm= M4qwUFAuOTBizszN NUnqOYlkOjRiaB?= NEnTN2ZFVVOR NXfucmRqcW6qaXLpeJMhfGinIHHjeIl3[XSrb36gc4YhfGinIFXHSnIhfHm{b4PpcoUhc2mwYYPlJIFv\CCjbIPvJIRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBxcG:|cHjvdplt[XSnZDDmc5JueyCxZjD0bIUh\G:5boP0doVidSC|aXfuZYxqdmdiZXzlcYVvfHNuIGPURXQ{KGGwZDDNRXBM MonENlI{ODd5M{W=
PCI-15B M2rjPWZ2dmO2aX;uJGF{e2G7 NHXWPXQxNTFyIN88US=> NW\aVGJVOjRiaB?= M4nidGROW09? M{\JVolvcGmkaYTzJJRp\SCjY4TpeoF1cW:wIH;mJJRp\SCHR1\SJJR6em:|aX7lJItqdmG|ZTDhcoQh[Wy|bzDk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gdIhwe3Cqb4L5cIF1\WRiZn;ycZMhd2ZidHjlJIRwf26|dILlZY0he2mpbnHsbY5oKGWuZX3lcpR{NCCVVFHUN{BidmRiTVHQTy=> MWKyNlMxPzd|NR?=
PCI-37A MVrGeY5kfGmxbjDBd5NigQ>? NF3sTooyKM7:TR?= M{DRclI1KGh? M{PRfmROW09? NE\IVZBld3ewcnXneYxifGW|IG\FS2YheHKxZIXjeIlwdg>? MlPENlI{ODd5M{W=
UM-22A MV3GeY5kfGmxbjDBd5NigQ>? MV6xJO69VQ>? NI\YWG8zPCCq Mor6SG1UVw>? Mny1[I94dnKnZ4XsZZRmeyCYRVfGJJBzd2S3Y4Tpc44> NYTkcm9JOjJ|MEe3N|U>
PCI-15B NHSw[ZVHfW6ldHnvckBCe3OjeR?= M4Pub|Eh|ryP MmLMNlQhcA>? MnvjSG1UVw>? MmDv[I94dnKnZ4XsZZRmeyCYRVfGJJBzd2S3Y4Tpc44> MVyyNlMxPzd|NR?=
PCI-15B Mn75TY53[XOrb36gRZN{[Xl? NETReXQzPCCq M3HnN2ROW09? NF3TOGxGSzVyPUW1PEBvVQ>? NHnkb20zOjNyN{ezOS=>
PCI-37A M1rtXGlvfmG|aX;uJGF{e2G7 NEnOUGYzPCCq M4HMbmROW09? M1GxS2VEPTB;MU[5OUBvVQ>? NVTaO4pLOjJ|MEe3N|U>
UM-22A NX3VSnpnUW64YYPpc44hSXO|YYm= NFrXSZgzPCCq MlzNSG1UVw>? NWXMSW5rTUN3ME2wMlMhdk1? MVSyNlMxPzd|NR?=
SCC-25 Mk[4TY53[XOrb36gRZN{[Xl? MmnsNlQhcA>? MYXEUXNQ MoPBSWM2OD1zMDDuUS=> MYWyNlMxPzd|NR?=
UM-22B MmnDTY53[XOrb36gRZN{[Xl? MlOzNlQhcA>? M3K5XmROW09? NEnFV3hGSzVyPUK0NlQhdk1? MmGyNlI{ODd5M{W=
PCI-37B MY\JcpZie2mxbjDBd5NigQ>? NV;BO5hVOjRiaB?= NHz0VotFVVOR MkLKSWM2OD1zN{K2JI5O M{CzXFIzOzB5N{O1
201T NH;YZWJHfW6ldHnvckBCe3OjeR?= NYL4N2Z3Oi53IN88US=> NWT4UII2PDhiaB?= NX;tVVdbTE2VTx?= NXuwZ41{cW6qaXLpeJMheGixc4Doc{1OSVCNIH\vcIxwf2mwZzDFS2Y> NWHnSVhVOjJ{NUi0O|Y>
273T  MX3GeY5kfGmxbjDBd5NigQ>? MUKyMlUh|ryP M1f2NlQ5KGh? NXni[49nTE2VTx?= MUfpcohq[mm2czDwbI9{eGixLV3BVGsh\m:ubH;3bY5oKEWJRh?= MmPhNlIzPTh2N{[=
A549 NHHkbVlHfW6ldHnvckBCe3OjeR?= MmHBNk42KM7:TR?= MlTVOFghcA>? NEnHZXNFVVOR NH\hbJNqdmirYnn0d{BxcG:|cHjvMW1CWEtiZn;scI94cW6pIFXHSi=> M{HrTlIzOjV6NEe2
201T  NYXCWGhsTnWwY4Tpc44hSXO|YYm= NF;uR|kyNzVxMUCg{txO NV;a[mRJPDhiaB?= NIP5Z4tFVVOR MVTicI9kc3NidHjlJJBpd3OyaH;yfYxifGmxbjDv[kBCc3RiaX7keYNm\CCkeTDWSWdHSw>? M3vuVFIzOjV6NEe2
H2052 MnvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTFwMEhCtVAvODRizszN MYWyNVk4ODh5NB?=
H2452 MljFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVG0O3ZiUUN3ME2zMlUzyrFzLkGzJO69VQ>? NVjrdGF6OjF7N{C4O|Q>
H28 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zS[GlEPTB;MD6zNuKyOC5yNzFOwG0> MWeyNVk4ODh5NB?=
MSTO-211H M1XDWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjLTWM2OD1zLkSyxtExNjB|IN88US=> M{LOWFIyQTdyOEe0
Hth83 NVXlZ5lqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXVfnB4PzJiaB?= M3vnT2ROW09? NHryS5NKSzVyPUOuN|AhyrFiMD62OkDPxE1? NITJRoQzOTJ{MES3Oy=>
C643 M2mxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYC3NkBp NVj3NoFKTE2VTx?= MUXJR|UxRTNwNkWgxtEhOS5{MjFOwG0> MmDRNlEzOjB2N{e=
8505C M2XObWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHr0WZQ4OiCq MWXEUXNQ M4jtOmlEPTB;Nz61OkDDuSBzLkGzJO69VQ>? MWGyNVIzODR5Nx?=
Hth74 NFrh[lhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3aVoQ4OiCq NFT5ZlVFVVOR Mm[0TWM2OD16LkW2JOKyKDFwMEGg{txO Mo\wNlEzOjB2N{e=
SW1736 NFG2[5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGf2ZYw4OiCq MX\EUXNQ NE[5bY5KSzVyPUmuNFUhyrFiMD61OUDPxE1? MXyyNVIzODR5Nx?=
Hth7 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoriO|IhcA>? NX\6enRXTE2VTx?= MV\JR|UxRTlwNk[gxtEhOC5|ODFOwG0> NH3wdFMzOTJ{MES3Oy=>
Hth104 M4PQZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moj6O|IhcA>? MUXEUXNQ MUnJR|UxRcLzMU[uPVghyrFiTlGg{txO M1HWWFIyOjJyNEe3
HTB3 NWLKS|l2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\jc3YxNTJyIN88US=> NGL1Vm0zPMLiaB?= MV3pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> M3LSNlE6OjJyMkW2
HT1376 NELP[nFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnETHgxNTJyIN88US=> NF22WY8zPMLiaB?= NIrpXFRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MYWxPVIzODJ3Nh?=
RT4 MnXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jXRVAuOjBizszN NHnVcmszPMLiaB?= NHeycm9qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MUSxPVIzODJ3Nh?=
J82 NV6xcGRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jmS|AuOjBizszN NHTHXoMzPMLiaB?= NHjXXXBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NUfvTWpnOTl{MkCyOVY>
CRL1749 M3rsXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWOwMVIxKM7:TR?= NYDwdZBkOjUEoHi= M4fLeolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MXexPVIzODJ3Nh?=
T24 NU[xcnNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{WydlAuOjBizszN NE\oPIkzPMLiaB?= NWXY[nRlcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MkjyNVkzOjB{NU[=
SUP NX7KNZMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHv1OY4xNTJyIN88US=> MXmyOOKhcA>? NFTpVZFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MorXNVkzOjB{NU[=
HTB9 M3qxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX:4[XpoOC1{MDFOwG0> MVuyOOKhcA>? NUL2WoNRcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MYSxPVIzODJ3Nh?=
ACC3 NWDRPZlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HC[VAuOTBizszN MXq3NkBp MUHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NXrDRYR2OTh4OUiwNlU>
ACC2 NYLaTnhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYOwMVExKM7:TR?= MnLlO|IhcA>? M3LUPIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz Ml22NVg3QThyMkW=
ACCM M1LVOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVGwMVExKM7:TR?= MVS3NkBp MnnkbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M17RRVE5Pjl6MEK1
ACC3 NFfwdJJCeG:ydH;zbZNqKEG|c3H5 M2rjTVAuOTBizszN NGS0UZI4OiCq MXrpcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 MkK1NVg3QThyMkW=
ACC2 M{XYXGFxd3C2b4Ppd4khSXO|YYm= MXOwMVExKM7:TR?= MWe3NkBp Ml7HbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= MYOxPFY6QDB{NR?=
ACCM NYHaXGt[SXCxcITvd4l{cSCDc4PhfS=> MVuwMVExKM7:TR?= NWnNOnJvPzJiaB?= M1rKO4lv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm= NHnZfYsyQDZ7OECyOS=>
EHMES-1 NX3u[FN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\0O|IhcA>? MVHEUXNQ NVrETGVWUUN3ME2xNE43KM7:TR?= NYX3dHFLOTh|NkSyOFg>
EHMES-10 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\hPIY4OiCq NXTHeGtNTE2VTx?= MljDTWM2OD1yLkOg{txO MkfENVg{PjR{NEi=
211H MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTER4l[PzJiaB?= MXTEUXNQ NF7H[2dKSzVyPUKuNkDPxE1? MmXUNVg{PjR{NEi=
H28 Ml;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYG3NkBp NIXQcVFFVVOR MUHJR|UxRTFwODFOwG0> M3HFR|E5OzZ2MkS4
H2052 NWHNc25yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33qO|czKGh? M{\FeWROW09? MXPJR|UxRThwMDFOwG0> M1j2TlE5OzZ2MkS4
H2452 NG\NUo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXq3NkBp MnzTSG1UVw>? NYPIbIlnUUN3ME21MlUh|ryP MnrMNVg{PjR{NEi=
CNE-1 NInuUmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TEdlAvOS1{NT62JO69VQ>? NUnjOGUyPDhiaB?= MmezTWM2OD1|Lk[g{txO M1vNT|E4PjNzNkS2
CNE-2 NUO1c5c3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPm[YwxNjFvMkWuOkDPxE1? M3HKNFQ5KGh? M3W5dmlEPTB;Nj6yJO69VQ>? M3m1[lE4PjNzNkS2
C666-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXewMlEuOjVwNjFOwG0> MV:0PEBp MXPJR|UxRTJ|LkSg{txO MWSxO|Y{OTZ2Nh?=
CNE-1 M2jKSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLVT4F6OC5zLUK1MlYh|ryP NEf4[JI4OiCq Mmf0TWM2OD1{LkOg{txO M3j2W|E4PjNzNkS2
CNE-2 M17pcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXXO4RsOC5zLUK1MlYh|ryP M{OxOFczKGh? M2DKV2lEPTB;Mz62JO69VQ>? NXH5OJQzOTd4M{G2OFY>
C666-1 MlL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvkWJZmOC5zLUK1MlYh|ryP M{XYTFczKGh? NEXsfpdKSzVyPUSuPFYh|ryP MW[xO|Y{OTZ2Nh?=
CNE-1 NYjxVJZDTnWwY4Tpc44hSXO|YYm= Mlf3OkDPxE1? NYjrOZdEOjRiaB?= NFvYc25l\WyjeYOgS|AwTzFiY3XscEBkgWOuZTDwdo9oemW|c3nvci=> NEPBRnkyPzZ|MU[0Oi=>
CNE-2 NWPido1{TnWwY4Tpc44hSXO|YYm= MmnZOkDPxE1? NYnwOHA3OjRiaB?= MYLk[YxigXNiR{CvS|Eh[2WubDDjfYNt\SCycn;ndoV{e2mxbh?= M1PxUlE4PjNzNkS2
C666-1 NHjZcmlHfW6ldHnvckBCe3OjeR?= NXv0OWdmPiEQvF2= MVOyOEBp MXXk[YxigXNiR{CvS|Eh[2WubDDjfYNt\SCycn;ndoV{e2mxbh?= Ml\BNVc3OzF4NE[=

... Click to View More Cell Line Experimental Data

体内研究 Vandetanib (2.5 mg/kg, 静脉注射)逆转 63%VEGF诱导的低血压,但是不会显著影响bFGF诱导的低血压。Vandetanib (100 mg/kg) 抑制79%肿瘤诱导的血管形成。Vandetanib (12.5-100 mg/kg, 口服处理) 作用于人类移植瘤,包括 Calu-6, PC-3, MDA-MA-231, SKOV-3, SW620, A549, A431, B16-F10(AP3) 和 Lewis 肺癌,显著抑制肿瘤生长,而对体重几乎没有影响。[1] Vandetanib单独作用于PC3wt移植瘤,施加似是而非的肿瘤生长刺激作用。Vandetanib按25 mg/kg低剂量处理PC3R移植瘤,与对照组相比,明显显著效果,而按50 mg/kg高剂量处理,与对照组相比,则显著抑制肿瘤生长。相反, Vandetanib 50 mg/kg 和Docetaxel 30 mg/kg 按高剂量联用作用于PC3R细胞,却具有显著的负相互作用。[3]Vandetanib 作用于携带肿瘤的小鼠,抑制肿瘤组织中的VEGFR-2 和EGFR磷酸化,显著降低肿瘤血管密度,增强肿瘤细胞凋亡,抑制肿瘤生长,促进生存,降低肝内转移数量,且上调肿瘤组织中的VEGF, TGF-alpha和EGF。Vandetanib处理与严重不良事件,包括ALT异常,骨髓抑制或体重减轻无关。[4]Vandetanib 作用于携带GEO结肠癌移植瘤(对EGFR 信号受抑制敏感)的裸鼠,抑制肿瘤生长,这种作用存在剂量依赖性。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

激酶抑制实验:

Vandetanib 与酶, 10 mM MnCl2, 和 2 μM ATP在聚(Glu, Ala, Tyr) 6:3:1随机共聚物底物包被的96孔板上温育。通过与小鼠IgG抗-磷酸酪氨酸4G10抗体,一种辣根过氧化物酶连接的羊抗鼠免疫球蛋白抗体,和2,2
细胞实验:

[1]

+ 展开
  • Cell lines: Calu-6, PC-3, MDA-MA-231, SKOV-3, SW620, A549, A431, B16-F10(AP3) 和 Lewis肺癌细胞
  • Concentrations: 0.1–100 μM
  • Incubation Time: 72 小时
  • Method:

    肿瘤细胞按预先制定密度接种在各自培养基中,确保在实验期间处于对数生长期 (PC-3细胞每孔500个;其他细胞每孔 1000 个)。 实验板在37oC下 含 CO2环境下温育24小时,然后加入 Vandetanib (0.1–100 μM) 或空白对照 (0.1% DMSO,在培养基中)。实验板再预温育72小时,然后使用beta 计数器通过测定 [3 H]胸甘渗透率而测评价细胞增殖。


    (Only for Reference)
动物实验:

[5]

+ 展开
  • Animal Models: 携带 PC-3, Calu-6, SKOV-3, 和 MDA-MB-231肿瘤的雌性无胸腺(nu/nu 基因型) Swiss小鼠
  • Formulation: 1% (v/v) 聚乙二醇溶液
  • Dosages: 12.5 mg/kg/day, 25 mg/kg/day, 50 mg/kg/day, 或 100 mg/kg/day
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 4 mg/mL (8.41 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
1% CMC Na
30mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 475.35
化学式

C22H24BrFN4O2

CAS号 443913-73-3
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03630120 Recruiting Thyroid Cancer|Thyroid Cancer Medullary|Differentiated Thyroid Cancer|Papillary Thyroid Cancer|Follicular Thyroid Cancer|Poorly Differentiated Thyroid Gland Carcinoma H. Lee Moffitt Cancer Center and Research Institute August 6 2018 Phase 2
NCT03291379 Recruiting Carcinoma Hepatocellular|Metastatic Colorectal Cancer Biocompatibles UK Ltd May 17 2017 Early Phase 1
NCT02638428 Recruiting Relapsed Pediatric Solid Tumor|Refractory Pediatric Solid Tumor|Relapsed Pediatric AML|Refractory Pediatric AML Samsung Medical Center|Ministry of Health Republic of Korea December 2015 Phase 2
NCT02495103 Recruiting Renal Cell Carcinoma|Hereditary Leiomyomatosis and Renal Cell Cancer|Papillary Renal Cell Carcinoma Sporadic National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 8 2015 Phase 1|Phase 2
NCT02530411 Recruiting Neoplasms Velindre NHS Trust|Cancer Research UK|AstraZeneca April 2015 Phase 2
NCT02239952 Recruiting Cancer|High-grade Glioma VU University Medical Center November 2014 Not Applicable

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

相关VEGFR产品

Tags: 购买Vandetanib (ZD6474) | Vandetanib (ZD6474)供应商 | 采购Vandetanib (ZD6474) | Vandetanib (ZD6474)价格 | Vandetanib (ZD6474)生产 | 订购Vandetanib (ZD6474) | Vandetanib (ZD6474)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID